Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 2, 2015, Pages 233-236

  Reid, Philip A ^a   McAllister, David A ^b   Boyd, A Christopher ^b   Innes, J Alastair ^a,b   Porteous, David ^b   Greening, Andrew P ^a,b   Gray, Robert D ^a,b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; BIOLOGICAL MARKER;

ADULT; BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; DISEASE COURSE; LUNG; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TIME; VITAL CAPACITY;

ADULT; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; LUNG; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TIME FACTORS; VITAL CAPACITY;

EID: 84921326781     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201407-1365LE     Document Type: Letter

References (15)

1. MacGregor G, Gray RD, Hilliard TN, Imrie M, Boyd AC, Alton EW, Bush A, Davies JC, Innes JA, Porteous DJ, et al. Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros 2008;7:352-358.
2. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008;178:444-452.
3. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 2010;9:193-198.
4. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ, Rainer M, Mt-Isa S, Voase N, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013;68:532-539.
5. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
6. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, Tümmler B, Vavrova V, De Boeck K. Pulmonary exacerbation: towards a definition for use in clinical trials: report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011;10:S79-S81.
7. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. Available from: http://www.R-project.org/
8. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1. Epidemiology and pathogenesis. Thorax 2007;62:360-367.
9. Sanders DB, Bittner RCL, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-632.
10. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
11. Wojewodka G, De Sanctis JB, Bernier J, Bérubé J, Ahlgren HG, Gruber J, Landry J, Lands LC, Nguyen D, Rousseau S, et al. Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS One 2014;9:e88567.
12. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, Walsh W, Packer K, Clark T, Carveth H, Chen J, et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS One 2012;7:e42748.
13. Vermeulen F, Proesmans M, Boon M, Havermans T, De Boeck K. Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax 2014;69:39-45.
14. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012;142:1259-1266.
15. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186:857-865.